Gland Pharma Initial Public Offering (IPO) opened today. What should investors do with this IPO – should they put money in it or skip it? Zee Business Managing Editor Anil Singhvi gives his sharp and incisive take on it! 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Gland Pharma IPO is open till Wednesday and the investors will be able to do a minimum investment of Rs 15,000. The price band of this share is between Rs 1490 and Rs 1500.

Watch Zee Business Tweet Video Below:

The Market Guru said that there was no doubt about the credentials of the company and the company has a strong product pipeline. Growth in the last three [financial] years are very strong with revenues rising by 27 per cent while the profits by over 51 per cent. 

The company has been able to get approval of 215 NDAs (New Drug Approvals) out of 267 which is likely to push growth further. The operations are incomparable to Indian companies and if the overseas companies are compared, the valuations of Glen Pharma look considerably cheaper.  

The only problem area is the presence of Chinese promoters. The company which has been in operations since 1978, was taken over by a Singapore-based company Fosun, which itself has Chinese promoters, he said. This means that this Indian company is a subsidiary of a Chinese company. 

The current sentiment around China and its companies could be a crucial factor he said. This is an offer for sale, which means that whatever money the investors put, will go to the Chinese promoters.  

But, otherwise there is no problem as far as its growth prospects, fundamentals and balance sheet is concerned, the Managing Editor said. 

The only risk that remains with this company could be on the part of the government regulations, he said.  

Keeping these things, Singhvi said he would like to take a neutral stance on this stock. He would have recommended investors to put money in this stock, if the promoters were not Chinese, he further added. 

See Zee Business Live TV Streaming Below:

He advised investors to not put money for listing gains only. Long term investment should be done with the view of China factor. High risk investors should put money into this IPO.